Celgene Corporation COO Jacqualyn Fouse to retire
Dr. Fouse will continue to serve as President and COO until April 1, and through June 30, she will serve as a strategic advisor to the management team.
Dr. Fouse will not stand for reelection to the Celgene Board of Directors at the upcoming Annual Meeting in June.
Dr. Fouse was promoted to President and Chief Operating Officer on March 1, 2016. In February 2016, she was elected to the Board of Directors.
Previously she was President, Global Hematology and Oncology since July 2014.
Dr. Fouse joined the Company in September 2010 as Senior Vice President and Chief Financial Officer and became Executive Vice President and Chief Financial Officer in February 2012.
Before Celgene, Dr. Fouse served as Chief Financial Officer of Bunge Limited, a global agribusiness and food company (Bunge), starting in July 2007.
Before Bunge, Dr. Fouse was at Alcon Laboratories serving as Senior Vice President, Chief Financial Officer, and Head of Corporate Strategy at Alcon Laboratories between 2002 and 2007.
She was the Chief Financial Officer at Swissair Group from 2001 to 2002. She held a variety of senior finance positions at Nestlé S.A. from 1993 to 2001, including serving as Group Treasurer of Nestlé from 1999 to 2001.
Dr. Fouse also worked in finance at Alcon from 1986 to 1993 and held several positions, including Manager Corporate Investments and Domestic Finance.
Earlier in her career, she worked at Celanese Chemical and LTV Aerospace and Defense.
Dr. Fouse earned a B.A. and an M.A. in Economics and a Ph.D. in Finance from the University of Texas at Arlington.
Since 2010, she has served as a member of the Board of Directors of Dick’s Sporting Goods (chairperson of the audit committee), an NYSE-listed company.
Dr. Fouse served on the Board of Directors of the Perrigo Company (member of the audit committee), an NYSE-listed company, from November 2012 to April 2016.
The Company also announced the promotion of Scott Smith to President and COO, effective April 1, 20177.
Mr. Smith serves as President, Global Inflammation and Immunology. He was Senior Vice President, Global Head of I & I.
He joined Celgene in 2008 as Vice President, Global Marketing Inflammation and Immunology.
From 2003 to 2008 Mr. Smith was with Biovail, holding positions of General Manager Biovail U.S., General Manager Biovail Canada and Global Commercial Head.
Prior to Biovail, Mr. Smith was with Pharmacia (formerly Upjohn) for 16 years where he held various positions including Vice President U.S. Sales, Vice President Marketing Europe based in Paris, Vice President and Commercial Lead for Canada based in Toronto, and Commercial and Regulatory Head for South East Asia based in Hong Kong.
In January 2017, Mr. Smith was named a Director of Titan Pharmaceuticals, a specialty pharmaceuticals company that develops therapeutics for select chronic diseases utilizing its innovative, long-term, continuous drug delivery platform, ProNeura.
Mr. Smith holds a BSc in Chemistry and an HBSc in Pharmacology and Toxicology from the University of Western Ontario and a Masters of International Business Management from the American Graduate School of International Management (Thunderbird). ■
LATEST MOVES FROM New Jersey
- Eagle Pharmaceuticals names Richard A. Edlin to board
- Tom Gebhardt chairman and CEO of Panasonic Corp. of North America
- Innophos appoints Kim Ann Mink as chairman of the board
- Symbiomix Therapeutics appoints David L. Stern as CEO
- NeuLion appoints Tim Alavathil as CFO
More inside POST
What a new leader has to learn Leadership